Oragenics Inc (OGEN)
0.322
-0.01 (-3.68%)
USD |
NYAM |
Jul 05, 16:00
0.3349
+0.01 (+4.01%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 37.48M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -52.30% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 2.096 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 96.40% |
News
Headline
Wire
Time (ET)
Yahoo
06/23 16:30
Yahoo
06/14 07:30
SA Breaking News
04/06 10:47
MT Newswires
04/06 07:58
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/16/2022* | -- | Results | Q2 2022 | -- | -0.04 | -- | |
| 05/13/2022 | -- | Results | Q1 2022 | -0.05 | -0.02 | -150.0% | |
| 11/15/2021 | -- | Results | Q3 2021 | -0.04 | -0.04 | 0.00% | |
| 08/16/2021 | -- | Results | Q2 2021 | -0.03 | -0.04 | 25.00% | |
| 05/03/2021 | -- | Results | Q1 2021 | -0.05 | -0.04 | -25.00% | |
| 03/02/2021 | -- | Results | Q4 2020 | -- | -0.08 | -- | |
| 11/10/2020 | -- | Results | Q3 2020 | -- | -0.08 | -- | |
| 08/14/2020 | -- | Results | Q2 2020 | -- | -0.08 | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus. |
| URL | https://www.oragenics.com |
| Investor Relations URL | http://www.oragenics.com/?q=investors |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 16, 2022 (est.) |
| Last Earnings Release | May. 13, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of July 05, 2022.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 16.68M |
| Net Income (TTM) | -16.53M |
| Total Assets (Quarterly) | 22.20M |
| Total Liabilities (Quarterly) | 1.663M |
| Shareholders Equity (Quarterly) | 20.54M |
| Cash from Operations (TTM) | -14.78M |
| Cash from Investing (TTM) | -- |
| Cash from Financing (TTM) | -0.2297M |
Ratings
Profile
Edit
| Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus. |
| URL | https://www.oragenics.com |
| Investor Relations URL | http://www.oragenics.com/?q=investors |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 16, 2022 (est.) |
| Last Earnings Release | May. 13, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| OGEN Tweets |